Labeling of monoclonal antibodies and antibody fragments with radiometals for immunoPET

2015 ◽  
pp. 106-120
Author(s):  
Reinier Hernandez ◽  
Lazura K Krasteva ◽  
Weibo Cai
Keyword(s):  
Monoclonal Antibodies ◽  
Antibody Fragments

scholarly journals Generation of Monoclonal Antibodies for Sensitive Detection of Pro-Inflammatory Protein S100A9

2021 ◽  
Vol 11 (10) ◽  
pp. 4659
Author(s):  
Eun-Jung Kim ◽  
Gyu-Min Im ◽  
Chang-Soo Lee ◽  
Yun-Gon Kim ◽  
Byoung Joon Ko ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Calcium Binding ◽  
Nucleotide Sequences ◽  
Antibody Fragments ◽  
High Yield ◽  
Antigen Binding ◽  
Hybridoma Cell Culture ◽  
Inflammatory Protein ◽  
Inflammatory Processes ◽  
Yield And Purity

The calcium-binding protein S100A9 regulates inflammatory processes and the immune response. It is overexpressed in a variety of inflammatory and oncologic conditions. In this study, we produced a recombinant human S100A9 (hS100A9) antigen with high yield and purity and used it to generate a hybridoma cell culture-based monoclonal anti-hS100A9 antibody. We selected five anti-hS100A9 antibodies from cell supernatants that showed high antigen binding efficiency and identified the nucleotide sequences of three antibodies: two with high effective concentration values and one with the lowest value. The antigen and antibody development procedures described herein are useful for producing large amounts of monoclonal antibodies against hS100A9 and other antigens of interest. The nucleotide sequences of the anti-hS100A9 monoclonal antibody revealed herein will be helpful in the generation of recombinant antibodies or antibody fragments against hS100A9.

scholarly journals David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments

Antibodies ◽  
2019 ◽  
Vol 8 (2) ◽  
pp. 28 ◽  
Author(s):  
Adam Bates ◽  
Christine A. Power
Keyword(s):  
Monoclonal Antibodies ◽  
Lower Cost ◽  
Biological Effects ◽  
Antibody Therapy ◽  
Antibody Fragments ◽  
Intracellular Targeting ◽  
Fast Pace ◽  
Binding Antibody ◽  
Multifunctional Molecules ◽  
Potential Use

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies have become the largest class of biopharmaceuticals with over 80 antibodies currently approved for a variety of disease indications. The development of smaller, antigen binding antibody fragments, derived from conventional antibodies or produced recombinantly, has been growing at a fast pace. Antibody fragments can be used on their own or linked to other molecules to generate numerous possibilities for bispecific, multi-specific, multimeric, or multifunctional molecules, and to achieve a variety of biological effects. They offer several advantages over full-length monoclonal antibodies, particularly a lower cost of goods, and because of their small size they can penetrate tissues, access challenging epitopes, and have potentially reduced immunogenicity. In this review, we will discuss the structure, production, and mechanism of action of EMA/FDA-approved fragments and of those in clinical and pre-clinical development. We will also discuss current topics of interest surrounding the potential use of antibody fragments for intracellular targeting and blood–brain barrier (BBB) penetration.

scholarly journals HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

2020 ◽  
Author(s):  
Betül Altunay ◽  
Agnieszka Morgenroth ◽  
Mohsen Beheshti ◽  
Andreas Vogg ◽  
Nicholas C. L. Wong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Monoclonal Antibodies ◽  
Molecular Imaging ◽  
Antibody Fragments ◽  
Drug Delivery Vehicles ◽  
Tumor Penetration ◽  
Drug Conjugates ◽  
Delivery Vehicles

Abstract Purpose The aim of the present paper is to review the role of HER2 antibodies, affibodies and nanobodies as vehicles for imaging and therapy approaches in breast cancer, including a detailed look at recent clinical data from antibody drug conjugates and nanobodies as well as affibodies that are currently under development. Results Clinical and preclinical studies have shown that the use of monoclonal antibodies in molecular imaging is impaired by slow blood clearance, associated with slow and low tumor uptake and with limited tumor penetration potential. Antibody fragments, such as nanobodies, on the other hand, can be radiolabelled with short-lived radioisotopes and provide high-contrast images within a few hours after injection, allowing early diagnosis and reduced radiation exposure of patients. Even in therapy, the small radioactively labeled nanobodies prove to be superior to radioactively labeled monoclonal antibodies due to their higher specificity and their ability to penetrate the tumor. Conclusion While monoclonal antibodies are well established drug delivery vehicles, the current literature on molecular imaging supports the notion that antibody fragments, such as affibodies or nanobodies, might be superior in this approach.

scholarly journals Exploring cellular biochemistry with nanobodies

2020 ◽  
Vol 295 (45) ◽  
pp. 15307-15327 ◽  
Author(s):  
Ross W. Cheloha ◽  
Thibault J. Harmand ◽  
Charlotte Wijne ◽  
Thomas U. Schwartz ◽  
Hidde L. Ploegh
Keyword(s):  
Monoclonal Antibodies ◽  
Membrane Proteins ◽  
Heavy Chain ◽  
Antibody Fragments ◽  
Single Domain ◽  
Single Domain Antibody ◽  
Chemical Functionalization ◽  
Domain Antibody ◽  
Cellular Biochemistry ◽  
Reducing Environment

Reagents that bind tightly and specifically to biomolecules of interest remain essential in the exploration of biology and in their ultimate application to medicine. Besides ligands for receptors of known specificity, agents commonly used for this purpose are monoclonal antibodies derived from mice, rabbits, and other animals. However, such antibodies can be expensive to produce, challenging to engineer, and are not necessarily stable in the context of the cellular cytoplasm, a reducing environment. Heavy chain–only antibodies, discovered in camelids, have been truncated to yield single-domain antibody fragments (VHHs or nanobodies) that overcome many of these shortcomings. Whereas they are known as crystallization chaperones for membrane proteins or as simple alternatives to conventional antibodies, nanobodies have been applied in settings where the use of standard antibodies or their derivatives would be impractical or impossible. We review recent examples in which the unique properties of nanobodies have been combined with complementary methods, such as chemical functionalization, to provide tools with unique and useful properties.

scholarly journals Virus Strain Discrimination Using Recombinant Antibodies

2000 ◽  
Vol 16 (1-2) ◽  
pp. 95-97 ◽  
Author(s):  
N. Boonham ◽  
I. Barker
Keyword(s):  
Monoclonal Antibodies ◽  
Polyclonal Antibodies ◽  
Recombinant Antibody ◽  
Plant Viruses ◽  
Antibody Fragments ◽  
Single Chain ◽  
Traditional Methods ◽  
Assay Sensitivity ◽  
Single Chain Fv ◽  
Selection Of

Most routine testing for plant viruses is currently carried out using monoclonal and polyclonal antibodies. Traditional methods of antibody production however can be time consuming and require the use of expensive cell culture facilities. Recombinant antibody technology however is starting to make an impact in this area, enabling the selection of antibody fragments in a few weeks compared with the many months associated with traditional methods and requires only basic microbiological facilities. Single chain Fv antibody fragments (scFv) have been selected from a synthetic phage-antibody library by affinity selection with purifiedPotato virus Y, ordinary strain (PVYO). The scFv selected was specific for PVY and detected 7 out of 9 isolates of PVYOwhilst it did not detect 15 isolates from the closely related necrotic strains PVYNand PVYNTN. In ELISA the scFv could be used to detect virus at concentrations of 50 ng/ml in plant sap and was shown to have similar limits of detection as commercially available PVY monoclonal antibodies. These results highlight the potential of the technology for the selection of strain specific antibodies with an affinity and assay sensitivity similar to traditional monoclonal antibodies and their use in viral diagnostics.

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011 ◽  
Vol 11 (11) ◽  
pp. 1433-1445 ◽  
Author(s):  
Gaetana Di Fede ◽  
Giuseppe Bronte ◽  
Sergio Rizzo ◽  
Christian Rolfo Cervetto ◽  
Gianfranco Cocorullo ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
State Of The Art ◽  
Antibody Fragments ◽  
Future Perspectives
Sign in / Sign up

Export Citation Format

Share Document